• DOI:10.1067/mcp.2001.113989
Corpus ID: 288484

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

@article{Atkinson2001BiomarkersAS,
  title={Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework},
  author={A. Atkinson and W. Colburn and V. DeGruttola and D. Demets and G. Downing and D. Hoth and J. Oates and C. Peck and R. Schooley and B. Spilker and J. Woodcock and S. Zeger},
  journal={Clinical Pharmacology & Therapeutics},
  year={2001},
  volume={69}
}

A. Atkinson, W. Colburn, +9 authors S. Zeger

Published 2001

Medicine

Clinical Pharmacology & Therapeutics

genome are dramatically reshaping the research and development pathways for drugs, vaccines, and diagnostics. The growth in the number of molecular entities entering the drug development pipeline has accelerated as a consequence of powerful discovery and screening technologies such as combinatorial chemistry, mass spectrometry, high throughput screening, celland tissue-based DNA microarrays, and proteomic approaches.1 As a consequence, there is an escalating number of therapeutic candidates… CONTINUE READING

View on Wiley

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed